Risk of endometrial cancer after RRSO in BRCA 1/2 carriers: a multicentre cohort study

被引：0

作者：

Pla-Juher, Helena ^{[1
,2
,4
]}

Pardo, Marta ^{[2
]}

Izquierdo, Angel J. ^{[2
,3
,4
]}

Darder, Esther ^{[3
,4
]}

Carbo, Anna ^{[1
,2
,4
]}

Munte, Elisabet ^{[5
]}

Torres-Esquius, Sara ^{[6
]}

Balmana, Judith ^{[6
]}

Lazaro, Concepcion ^{[5
,7
]}

Brunet, Joan M. ^{[1
,2
,3
,4
]}

Barretina-Ginesta, Maria-Pilar ^{[1
,2
,4
]}

机构：

[1] Hosp Univ Dr Josep Trueta, Catalan Inst Oncol, Med Oncol, Avinguda Franca S-N, Girona 17707, Spain

[2] Inst Invest Biomed Girona IDIBGI, Precis Oncol Grp OncoGIR Pro, Girona, Spain

[3] IDIBGI, Catalan Inst Oncol, Hereditary Canc Program, Girona, Spain

[4] Dept Epidemiol & Canc Register, Girona, Spain

[5] IDIBELL, Catalan Inst Oncol, Hereditary Canc Program, Barcelona, Spain

[6] Vall dHebron Hosp, Dept Med Oncol, Barcelona, Spain

[7] Inst Salud Carlos III, Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain

来源：

CLINICAL & TRANSLATIONAL ONCOLOGY | 2024年 / 26卷 / 04期

关键词：

Endometrial cancer; Breast cancer; Risk-reducing salpingo-oophorectomy; BRCA; Mutation; Hysterectomy; Tamoxifen; Carcinosarcoma; Serous carcinoma; Endometrioid carcinoma; REDUCING SALPINGO-OOPHORECTOMY; UTERINE SEROUS CARCINOMA; BRCA2; MUTATIONS; BREAST-CANCER; WOMEN; HYSTERECTOMY; METAANALYSIS; SURGERY; TIME;

D O I：

10.1007/s12094-023-03312-4

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Objective To know the risk of endometrial cancer (EC) in a population of women with BRCA 1/2 pathogenic or likely pathogenic variants after risk-reducing salpingo-oophorectomy (RRSO).Methods The study cohort included data from 857 women with BRCA mutations who underwent RRSO visited four hospitals in Catalonia, Spain, from January 1, 1999 to April 30, 2019. Standardized incidence ratio (SIR) of EC was calculated in these patients using data from a regional population-based cancer registry.Results After RRSO, eight cases of EC were identified. Four in BRCA 1 carriers and four in BRCA2 carriers. The expected number of cases of EC was 3.67 cases, with a SIR of 2.18 and a 95% CI (0.93-3.95).Conclusions In our cohort, the risk of EC in BRCA1/2 carriers after RRSO is not greater than expected. Hysterectomy is not routinely recommended for these patients.

引用

页码：1033 / 1037

页数：5

共 50 条

[31] Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers
Gronwald, Jacek
Robidoux, Andre
Kim-Sing, Charmaine
Tung, Nadine
Lynch, Henry T.
Foulkes, William D.
Manoukian, Siranoush
Ainsworth, Peter
Neuhausen, Susan L.
Demsky, Rochelle
Eisen, Andrea
Singer, Christian F.
Saal, Howard
Senter, Leigha
Eng, Charis
Weitzel, Jeffrey
Moller, Pal
Gilchrist, Dawna M.
Olopade, Olufunmilayo
Ginsburg, Ophira
Sun, Ping
Huzarski, Tomasz
Lubinski, Jan
Narod, Steven A.
BREAST CANCER RESEARCH AND TREATMENT, 2014, 146 (02) : 421 - 427
[32] Adequacy of risk-reducing gynaecologic surgery in BRCA1 or BRCA2 mutation carriers and other women at high risk of pelvic serous cancer
Kiely, B. E.
Friedlander, M. L.
Milne, R. L.
Stanhope, L.
Russell, P.
Jenkins, M. A.
Weideman, P.
McLachlan, S. A.
Grant, P.
Hopper, J. L.
Phillips, K. A.
FAMILIAL CANCER, 2011, 10 (03) : 505 - 514
[33] Prospective evaluation of alcohol consumption and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers
Cybulski, Cezary
Lubinski, Jan
Huzarski, Tomasz
Lynch, Henry T.
Randall, Susan Armel
Neuhausen, Susan L.
Senter, Leigha
Friedman, Susan
Ainsworth, Peter
Singer, Christian
Foulkes, William D.
Narod, Steven A.
Sun, Ping
Kotsopoulos, Joanne
BREAST CANCER RESEARCH AND TREATMENT, 2015, 151 (02) : 435 - 441
[34] Tamoxifen and the risk of ovarian cancer in BRCA1 mutation carriers
Vicus, Danielle
Rosen, Barry
Lubinski, Jan
Domchek, Susan
Kauff, Noah D.
Lynch, Henry T.
Isaacs, Claudine
Tung, Nadine
Sun, Ping
Narod, Steven A.
GYNECOLOGIC ONCOLOGY, 2009, 115 (01) : 135 - 137
[35] Plasma folate, vitamin B-6, and vitamin B-12 and breast cancer risk in BRCA1- and BRCA2-mutation carriers: a prospective studyt
Kim, Shana J.
Zuchniak, Anna
Sohn, Kyoung-Jin
Lubinski, Jan
Demsky, Rochelle
Eisen, Andrea
Akbari, Mohammad R.
Kim, Young-In
Narod, Steven A.
Kotsopoulos, Joanne
AMERICAN JOURNAL OF CLINICAL NUTRITION, 2016, 104 (03) : 671 - 677
[36] Risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a 30-year semi-prospective analysis
Basu, N. N.
Ingham, S.
Hodson, J.
Lalloo, F.
Bulman, M.
Howell, A.
Evans, D. G.
FAMILIAL CANCER, 2015, 14 (04) : 531 - 538
[37] Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers
Leendert H Zaaijer
Helena C van Doorn
Marian J E Mourits
Marc van Beurden
Joanne A de Hullu
Muriel A Adank
Luc R C W van Lonkhuijzen
Hans F A Vasen
Brigitte F M Slangen
Katja N Gaarenstroom
Ronald P Zweemer
Peggy M L H Vencken
Caroline Seynaeve
Mieke Kriege
British Journal of Cancer, 2016, 115 : 1174 - 1178
[38] Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers
Zaaijer, Leendert H.
van Doorn, Helena C.
Mourits, Marian J. E.
van Beurden, Marc
de Hullu, Joanne A.
Adank, Muriel A.
van Lonkhuijzen, Luc R. C. W.
Vasen, Hans F. A.
Slangen, Brigitte F. M.
Gaarenstroom, Katja N.
Zweemer, Ronald P.
Vencken, Peggy M. L. H.
Seynaeve, Caroline
Kriege, Mieke
BRITISH JOURNAL OF CANCER, 2016, 115 (10) : 1174 - 1178
[39] Risk factors for sexual dysfunction in BRCA mutation carriers after risk-reducing salpingo-oophorectomy
Chan, Jessica L.
Senapati, Suneeta
Johnson, Lauren N. C.
DiGiovanni, Laura
Voong, Chan
Butts, Samantha F.
Domchek, Susan M.
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2019, 26 (02): : 132 - 139
[40] Folic acid supplement use and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a case-control study
Kim, Shana J.
Zhang, Cindy X. W.
Demsky, Rochelle
Armel, Susan
Kim, Young-In
Narod, Steven A.
Kotsopoulos, Joanne
BREAST CANCER RESEARCH AND TREATMENT, 2019, 174 (03) : 741 - 748

← 1 2 3 4 5 →